Document:

EX-10.r

 Exhibit 10r 
 *Confidential Treatment Requested 
 This text is a free
translation from the French language and is supplied solely for information purposes. 
 Only the original version in the
French language has legal force. 
  
  

SANOFI PHARMA BRISTOL-MYERS SQUIBB 
 General Partnership With a Capital of 
 50.000 Euro 

Head Office: 54 La Boétie Street 75008 Paris France 
 Trade and Companies Register of Paris 408 017 929 
 INTERNAL REGULATIONS

 January 1, 2013 
  

 
 *CONFIDENTIAL TREATMENT REQUESTED.
CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

							
	 TABLE OF CONTENTS
  
	   
 

	ARTICLE 1	  
	DEFINITIONS	  
			
	 1.1
	 	 Defined Terms
	  	 	1	  
	 1.2
	 	 Additional Defined Terms
	  	 	3	  
	
	ARTICLE 2	  
	POWERS AND OBLIGATIONS OF THE MANAGER(S)	  
			
	 2.1
	 	 Powers
	  	 	4	  
	 2.2
	 	 Limitation of Powers
	  	 	4	  
	 2.3
	 	 Actions for Patents and Trademarks
	  	 	4	  
	
	ARTICLE 3	  
	DISSOLUTION	  
			
	 3.1
	 	 Dissolution
	  	 	5	  
	 3.2
	 	 Product Sale Withdrawal
	  	 	5	  
	 3.3
	 	 Effects of Dissolution
	  	 	5	  
	
	ARTICLE 4	  
	MISCELLANEOUS	  
			
	 4.1
	 	 Notifications
	  	 	5	  
	 4.2
	 	 Governing law
	  	 	7	  
	 4.3
	 	 Execution of a Writ
	  	 	7	  
	 4.4
	 	 Litigations
	  	 	7	  
	 4.5
	 	 Securities
	  	 	7	  
	 4.6
	 	 Relative Effect
	  	 	7	  
	 4.7
	 	 Divisibility
	  	 	8	  
	 4.8
	 	 Transfer
	  	 	8	  
	 4.9
	 	 Agreements
	  	 	8	  
	 4.10
	 	 Entire Agreement
	  	 	8	  
	 4.11
	 	 Waivers and Modifications
	  	 	8	  
	 4.12
	 	 Exclusion of Creditors
	  	 	8	  
	 4.13
	 	 Duplicate
	  	 	8	  
	 4.14
	 	 Effective Date
	  	 	8	  
	 4.15
	 	 Applicable Language
	  	 	9	  
	 4.16
	 	 Capitalized Terms
	  	 	9	  
	
	APPENDICES	  
		
	 APPENDIX 1.1 Territory A
	  			

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 BETWEEN THE UNDERSIGNED: 

 

	1.	Sanofi Participations, a single-shareholder simplified stock company with a capital of 40.000 Euro, having its Head Office at 54 La Boétie Street 75008 Paris,
France, registered with the Trade and Companies Register of Paris under number 407 571 725 (“Sanofi Partner”), a subsidiary indirectly and entirely held by Sanofi, a limited company with a capital of 2.681.837.622 Euro, having its
Head Office at 54 La Boétie Street 75008 Paris, France, registered with the Trade and Companies Register of Paris under number 395 030 844 (“Sanofi”), and 

 

	2.	BMS Investco SAS, a simplified stock company with a capital of 40.000 Euro, having its Head Office at 3, Joseph Monier Street, 92500 Rueil Malmaison, registered with
the Trade and Companies Register of Nanterre under number 407 846 195 (“BMS Partner”), a subsidiary directly and indirectly entirely held by Bristol-Myers Squibb Company, registered in Delaware (United States of America), having its
Head Office at 345 Park Avenue, New York, NY 10154 (“BMS”). 

 INTRODUCTION

 The Partners have formed a general partnership Sanofi Pharma Bristol-Myers Squibb (the “Company”).

 The purpose of the Company is to allow the modification of the methods of joint development and marketing by the two Partners
of the Company, for the pharmaceutical products based on the two molecules Irbesartan and Clopidogrel which were discovered and patented by Sanofi and developed together with BMS. The Partners have carried out a new form of the Company’s
Articles of Association and of their Agreements specifically to enable the performance of this activity by way of lease management provided under the Company to another Company of the Sanofi group. 

The Partners have agreed, according to the terms of Article 15.4 of the Company’s Articles of Association, to modify the existing
internal regulations for the purpose of completing and detailing the Articles of Association to reflect the mutually agreed upon modifications. The Modified Internal Regulations, (hereinafter the “Internal Regulations”), are set
forth in detail below. 
 ARTICLE 1: DEFINITIONS 
  

	1.1	Defined Terms. When used in the Internal Regulations, the following terms shall have the meanings below: 

“Clopidogrel License Agreement”. The License Agreement for Intellectual Property and Delivery of Clopidogrel dated June 6, 1997, as
last amended on the date hereof (or as further amended according to Article 2.2. hereof), between the Company and Sanofi regarding the license of certain patents, trademarks and know-how for Clopidogrel and Clopidogrel Products of Sanofi to the
Company provided that Sanofi is paid the Development Fee (as these terms are defined within this Amended Agreement). 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 1 

 “Know-How License Agreement”. The License Agreement for Product Know-How dated June 6,
1997, as last amended on the date hereof (or as further amended according to Article 2.2. hereof), between the Company, Sanofi and BMS pursuant to the Development Agreement, the use of company names by the Company and the development of Irbesartan
and Clopidogrel as of June 6, 1997, provided that a Know-How Fee is paid (as this term is defined within this Amended Agreement). 

“Irbesartan License Agreement”. The License Agreement for Intellectual Property dated June 6, 1997, as last amended on the date
hereof (or as further amended according to article 2.2. hereof), between the Company and Sanofi regarding the license of certain patents, trademarks and know-how for Irbesartan and Irbesartan Products of Sanofi to the Company, provided that Sanofi
is paid the Development Fee (as this term is defined thereof). 
 “Partners”. The Sanofi Partner and BMS Partner and each of
their successors and beneficiaries; being however understood that any Partner without shareholdings shall be considered as retired from its position as Partner of the Company. 
 “Clopidogrel”. The chemical molecule discovered and patented by Sanofi and known under the SR 25990C code, whose unregistered international name is Clopidogrel Hydrogenosulphate.

 “Lease Management Agreement”. The business lease management agreement concluded January 1, 2013 between the Company and
SWIND. 
 “Termination Date”. December 31, 2018. 
 “Manager”. The person appointed, according to the law and to the Company’s articles of association, as manager of the Company, while specifying that on the date hereof the manager is
Sanofi Partner. 
 “Irbesartan”. The chemical molecule discovered and patented by Sanofi known under the SR 47436 code, whose
unregistered international name is Irbesartan. 
 “Person”. Any individual, partnership, company, including limited
company, general partnership, joint venture company, simplified stock company, joint-venture, association, trust or any other entity or administration or governmental agency or their subdivisions as well as any union or group considered to be
a person according to Section 13(d) of US Securities and Exchange Act of 1934 modified. 
 “Product”. The Clopidogrel
Product or a Irbesartan Product and “Products” indicates a Clopidogrel Product and a Irbesartan Product. 

“Clopidogrel Product”. (i) a product having Clopidogrel as sole active ingredient, in its finished form,
marketed under Plavix® and Iscover® trademarks or any other trademark whose similarity may generate confusion or which replaces one of them or (ii) a product (a “FDC Clopi
Identifié”) containing as sole active ingredients a combination of Clopidogrel and acetylsalicylic acid, in finished form, traded under Duoplavin®, CoPlavix® and DuoCover® trademarks or any other trademark whose similarity may generate confusion or which replaces one of them. The term
Clopidogrel Product excludes any other fixed-dose combination containing Clopidogrel. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 2 

 “Irbesartan Product”. (i) a product having Irbesartan as sole
active ingredient, in its finished form, marketed under Aprovel®, Karvea® and Avapro® trademarks or any other trademark whose similarity may generate confusion or which replaces one of them or (ii) a product (a “FDC Irbe
Identifié”) containing as sole active ingredients a combination of Irbesartan and Hydrochlorothiazide, in finished form, traded under CoAprovel®, Avalide® and Karvezide® trademarks or any other trademark whose similarity may generate confusion or which replaces one of them. The term
Irbesartan Product excludes any other fixed-dose combination containing Irbesartan. 
 “Affiliated Company”. In reference to a
Person, indicates any other Person controlling, controlled by, or under the joint control with, this Person; being however understood that, as regards Sanofi, the definition of Affiliated Company excludes L’Oreal. For the purpose of this
definition, “control” indicates (i) the direct or indirect power to orientate the management of a Person or to veto any significant decision related to the management of a Person, in each of these cases either by holding of securities
or shares with right of vote, by contract or by any other means, (ii) the direct or indirect holding of shares (excluding shares in a private company) representing at least 50% of the voting rights of a Person or (iii) holding at least 50%
of the shares of a private company. 
 “Articles of Association”. The Company’s updated Articles of Association effective
as of January 1, 2013. 
 “SWIND”. The company Sanofi Winthrop Industry, a French limited liability company having its
Head Office at 20, Raymond Aron Avenue, 92160 Antony, registered with the Trade and Companies Register of Nanterre under number 775 662 257. 

“Territory A”. The countries and geographical areas described in Appendix 1.1 enclosed hereof. 

 

	1.2	Additional Defined Terms. The following additional defined terms shall have the meaning stipulated by the articles listed below: 

 

			
	 Defined Term
	  	Definition Article
	BMS Partner	  	Introduction
	Sanofi Partner	  	Introduction
	BMS	  	Introduction
	CCI	  	4.4
	Dispute	  	4.4
	Notifications	  	4.1
	Dispute Notification	  	4.4
	Internal Regulations	  	Introduction
	Sanofi	  	Introduction
	Company	  	Introduction

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 3 

 ARTICLE 2: POWERS AND OBLIGATIONS OF THE MANAGER(S) 

 

	2.1	Powers. The Manager(s) shall have all powers to perform all the management deeds included in the Company purpose, subject to the decisions mentioned in
article 2.2 hereafter. The Manager(s) shall ensure that any contract mentioned in articles 2.2(d) and 2.2(e) hereafter concluded by the Company expressly stipulate that BMS Partner benefits from a stipulation for third parties allowing it to use for
and on behalf of the Company the rights which the latter benefits from according to this agreement. 

  

	2.2	Limitation of powers. The Manager(s) decisions set forth below shall not be valid unless or until they are authorized in writing and in advance by a BMS
Partner: 

  

	 	(a)	To modify these Internal Rules of the Company; 

  

	 	(b)	To request the initiation of proceedings for conciliation (according to Article L. 611-4 of the Commercial Code), for safeguard (according to Book VI of Title II of the
Commercial Code) or the appointment of an ad-hoc agent (according to Article L. 611-3 of the Commercial Code), on behalf of the Company or one of its subsidiaries; 

 

	 	(c)	To proceed to or to submit for the approval of partners any capital increase or issue of securities by the Company; 

 

	 	(d)	To modify or to terminate the Clopidogrel License Agreement, the Irbesartan License Agreement, the Know-How License Agreement or the Lease Management Agreement;

  

	 	(e)	To conclude or wind-up any Agreement (including any transaction within a litigation) involving one or several actual or potential payments by the Company, higher than
[*] cumulatively; 

  

	 	(f)	To implement any decision covered by Articles 12.3 (a), (b), (c) and (e) of the Articles of Association; 

 

	 	(g)	To conclude or wind-up any transaction within a litigation by way of which the Company admits having committed an error or wrongdoing. 

 

	2.3	Actions for Patents and Trademarks. The Manager(s) shall be able to initiate proceedings or to act on behalf of the Company (i) against a third party
for the violation of any patent or trademark licensed to the Company, (ii) in defense, against a legal action started by a third party against the Company, Sanofi Partner or one of their Affiliated Companies, for the counterfeit of a patent
and/or a trademark regarding Irbesartan, Clopidogrel or one of the two Products in Territory A or (iii) in defense against any legal action commenced by a third party for the invalidity or the nullity of any patent whatsoever registered in the
name of the Company. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 4 

 ARTICLE 3: DISSOLUTION 

 

	3.1	Dissolution. Until the Termination Date, Sanofi Partner and BMS Partner undertake not to participate to any operation, not to make any decision and not to
propose any modification of their Articles of Association or any decision that may have as purpose or effect their voluntary dissolution for any reason whatsoever, without having the prior agreement in writing of the other Partner.

  

	3.2	Product Sale Withdrawal. Should a Product be withdrawn from sale in Territory A, the Partners shall modify the Company’s Articles of Association in
order to remove any reference to the development, purchase, sale, marketing, advertising or trading of this Product. 

  

	3.3	Effects of Dissolution. Notwithstanding the effects of dissolution detailed in the Articles of Association, in case of dissolution of the Company,

  

	 	(a)	The Company shall assign or license to a Person mutually acceptable by the two Partners all the remaining assets of the Company as well as the rights and obligations it
has by way of the Clopidogrel License Agreement, Irbesartan License Agreement, and the Know-How License Agreement, except for the rights to company names and trademarks, containing the terms: “Sanofi”, “BMS” or
“Bristol-Myers Squibb”; 

  

	 	(b)	The products of such sale shall be allocated as set forth below and in the following order of priority: 

 

	 	(i)	For the payment of debts and liabilities of the Company and liquidation costs; 

 

	 	(ii)	The balance, if any, for the impoundment of the amounts which the Partners shall consider reasonably necessary for the contingent, non-liquidated or unforeseen
liabilities or for the obligations of the Company or of the Partners issued from or related to the Company. By mutual agreement of the Partners, such amounts can be deposited in a bank chosen by them and authorized to act as impoundment for the
withdrawals intended to cover the aforementioned debts and obligations 

  

	 	  	and, upon the expiry of the period determined by the Partners, to distribute the balance as stipulated in paragraph (iii) hereafter; and 

 

	 	(iii)	The balance, if any, shall be distributed to the Partners in proportion to their shareholdings. 

 ARTICLE 4: MISCELLANEOUS 
  

	4.1	Notifications. All the notifications, complaints, requests, formal demands and other communications (hereinafter collectively referred to as the
“Notifications”) shall be made in writing and shall be delivered in person, by hand, by registered letter, by mail with acknowledgement of receipt, to the Persons and addresses below: 

For the Company, at: 
 Sanofi Pharma Bristol-Myers Squibb 
 54 La Boétie street 

75008 Paris, France 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 5 

 To: Legal Director 
 Fax: (33 1) 01.53.77.40.85 
 To: Vice President, Alliance Management

 For BMS Partner, at: 
 BMS Investco S.A.S 
 France 

3, Joseph Monier Street 
 92500 Rueil Malmaison 
 To: President 

And a copy at: 

Bristol-Myers Squibb Company 
 Route 206 & Province Line Road 
 Princeton, NJ 08543 USA 

To: Alliance Manager 
 and: 
 Wilmer Cutler Pickering Hale and Dorr LLP 

7 World Trade Center 
 250 Greenwich Street 
 New York, New York 10007 USA 

To: [omitted] 

For Sanofi Partner, at: 
 Sanofi 
 54 La Boétie Street 

75008 Paris, France 
 To: Senior Vice President, Legal Affairs and General Counsel et Vice President, Alliances & Partnerships 
 and a copy to: 
 Weil, Gotshal & Manges 

2, Baume Street 

75008 Paris 
 To:
[omitted] 
 Each of the Partners can designate another recipient (and/or change its address) for the Notifications, by way of a
Notification made according to this article. All the Notifications made according to this article shall be considered as being sent upon the date of their reception when delivered in person, by hand, or ten (10) working days following the
delivery by registered mail or with acknowledgement of receipt. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 6 

	4.2	Governing law. These Internal Regulations as well as the related rights and obligations shall be governed by the French law. 

 

	4.3	Execution of a Writ. Each of the Partners acknowledges that the allocation of damages shall not stand for satisfactory rehabilitation in case of
non-fulfillment of one of the obligations stipulated herein. Consequently, the execution of a writ for these obligations shall be required to the maximum extent permitted by law. 

 

	4.4	Litigations. In case of litigations, claims, disputes or disagreements (a “Dispute”) resulting from or related to these Internal Rules,
including any issue regarding the validity, existence and termination of these Internal Rules, the Partners shall first try to settle their Dispute by negotiation. This process of negotiation shall be considered open when one of the Partners sends a
notification in writing (a “Notification of Dispute”) to the other Partner. Should a Dispute submitted to the negotiation procedure according to the aforementioned requirements not be definitively settled within a period of 30 days
upon the reception by one of the Partners of the Notification of Dispute, the Dispute shall be deferred to a mediation procedure in accordance with the Mediation Regulations of the International Chamber of Commerce (the “CCI”). The
mediation court shall be composed of three mediators. Each Partner shall appoint a mediator. The two mediators appointed shall appoint the president of the mediation court. If one of the Partners does not appoint a mediator in the petition for
mediation or within the 30 days upon the reception of a notification in writing stating the appointment of a mediator by the other Partner, the aforementioned mediator shall be appointed by the CCI. Should the two mediators appointed by the Partners
fail to reach an agreement on the appointment of a third mediator within a period of 30 days upon the appointment of the second mediator, the third mediator shall be appointed by the CCI. The mediation procedure shall be held in Paris, France and
the proceedings shall be conducted in English. Notwithstanding any contrary clause in the Mediation Regulations of the International Chamber of Commerce, each Partner shall bear its own costs and charges related to the aforementioned mediation
procedure and all related procedures, legal fees included. Each Partner shall continue to fulfill its obligations according to the Internal Regulations and the provisions of the Internal Regulations shall be further applied until the settlement of
this Dispute. 

  

	4.5	Titles. All titles and subtitles of the Internal Regulations are for convenience only and none of them shall affect the meaning or influence the
interpretation thereof. 

  

	4.6	Relative Effect. The Internal Regulations are binding upon and benefit to the Partners and their successors and authorized assignees and no express or
implicit provision shall be construed as granting rights, advantages or remedies to any third parties, of any nature whatsoever. Therefore, the Internal Regulations shall no longer bind and benefit to any Partner that would no longer hold at least a
share in the Company, as of the date when it would no longer hold at least a share in the Company. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 7 

	4.7	Divisibility. If one of the stipulations of the Internal Regulations is null, illegal or incompatible with the legal or statutory provisions, the other
stipulations of the Internal Regulations shall remain in full force and effect as far as the economic and legal substance of the operations covered herein is not unfavorably affected for any of the Partners. Since one stipulation of the Internal
Regulations is determined as null, illegal or incompatible with legal or statutory provisions, or impossible to execute, the Partners undertake to negotiate in good faith the modification of Internal Regulations in order to reflect as faithfully as
possible the original intention of the Partners so as the operations stipulated herein can be performed as far as possible according to the initial plan. 

  

	4.8	Transfer. This agreement shall not be transferred by one of the Partners without the authorization of the other Partner. 

 

	4.9	Agreements. All the agreements or authorizations of the deeds or issues required by the Internal Regulations shall be made in writing and shall concern
exclusively the specific deed or issue for which the agreement or authorization is given, and shall not relieve any of the Partners from the obligation to obtain, as the case may be, the agreement or authorization required by the Internal
Regulations for another deed or issue. 

  

	4.10	Entire Agreement. As the Internal Regulations and the Articles of Association express the entire agreement of the Partners regarding their purpose, they
annul and replace any prior verbal or written agreements between the Partners and their Affiliated Companies, concerning this purpose and not stipulated herein or in the Articles of Association 

 

	4.11	Waivers and Modifications. No modification of the Internal Regulations shall be valid unless it is subject to a written document signed by the two
Partners and expressly refers to the Internal Regulations or to the Articles of Association, mentioning the intention of Partners to modify the Internal Regulations or the Articles of Association. Any waiver of any stipulations hereof shall be made
in a written document signed by the interested Partner, provided that no waiver shall be construed as a future waiver or a waiver of the benefit of any other requirements or stipulations hereof. 

 

	4.12	Exclusion of Creditors. The provisions of the Internal Regulations are presumed to govern the relations between Partners and the relations between
Partners and the Company. The Internal Regulations have not been presumed to benefit to non- Partner creditors and no right shall be granted to non-Partner creditors by way of the provisions hereof. 

 

	4.13	Duplicate. The Internal Regulations can be signed in several copies, each of them being an original copy, but the whole shall constitute a unique
instrument. 

  

	4.14	Effective Date. The Internal Regulations, signed today, shall enter into force January 1, 2013. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 8 

	4.15	Applicable Language. The Partners acknowledge that the Internal Regulations can be translated into English. The Partners confirm that the French version
of the Internal Regulations shall prevail. 

  

	4.16	Capitalized Terms. The capitalized terms which are not defined by these Internal Regulations shall have the meaning provided in the Articles of
Association. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 9 

 Executed this 1st day of January, 2013. 

 

			
	SANOFI PARTICIPATIONS
		
	By:	 	 /s/ Gilles Boisson

		 	 Gilles Boisson

Authorized Representative

	
	BMS INVESTCO S.A.S.
		
	By:	 	 /s/ Jean-Christophe Barland

		 	 Jean-Christophe Barland

CEO

 [Signature Page to Internal Regulations] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 APPENDIX 1.1 
 Clopidogrel Product and Irbesartan product: 
  

	 	-	Germany, 

	 	-	Belgium, 

	 	-	Spain, 

	 	-	Greece, 

	 	-	Italy, 

	 	-	Netherlands, 

	 	-	Portugal, 

	 	-	Switzerland. 

 Clopidogrel Product only:

  

	 	-	Austria, 

	 	-	South Korea, 

	 	-	Cyprus, 

	 	-	Denmark, 

	 	-	Finland, 

	 	-	Hong-Kong, 

	 	-	Iceland, 

	 	-	Israel, 

	 	-	Ireland, 

	 	-	Norway, 

	 	-	Sweden, 

	 	-	Taiwan, 

	 	-	France (metropolitan). 

 For Irbesartan only:

  

	 	-	France (DOMTOM included) 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSIONEX-10.s

 Exhibit 10s 
 *Confidential Treatment Requested 
 AMENDMENT 

TO THE 

PARTNERSHIP AGREEMENT 
 OF 
 BRISTOL-MYERS SQUIBB SANOFI PHARMACEUTICALS HOLDING 

PARTNERSHIP 
 This Amendment (this “Amendment”), dated as of January 1, 2013 (the “Effective Date”) to the Partnership Agreement (the “Partnership Agreement”) of
Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership (“JVB”), dated as of January 1, 1997, by and between sanofi-aventis U.S. LLC (as successor-in-interest to Sanofi Pharmaceuticals, Inc., the “Sanofi
Partner”) and Bristol-Myers Squibb Investco, L.L.C. (or any successor-in-interest, the “BMS Partner” and together with the Sanofi Partner, the “Parties” and, individually, each a “Party”).
Except as otherwise noted, any capitalized terms not herein defined shall have the meaning ascribed to them in the Partnership Agreement. 
 WHEREAS, pursuant to a master restructuring agreement (“Master Agreement”), dated as of September 27, 2012 by and between Sanofi (“Sanofi”) and Bristol-Myers Squibb
Company (“BMS”), Sanofi and BMS have agreed to simplify the overall governance, operating and financial principles of their alliance with respect to (i) Irbesartan Products worldwide (other than in Japan, which is not in their
alliance) and (ii) Clopidogrel Products worldwide (other than in Japan, which is not in their alliance, and in the United States) (the “Restructuring”); 
 WHEREAS, as part of the Restructuring, the Parties wish to amend certain provisions of the Partnership Agreement to reflect the transfer to sanofi-aventis U.S. LLC of all of JVB’s rights and
obligations with respect to the distribution and commercialization of the Products (other than with respect to Clopidogrel Products in the United States of America) in Territory B1 (as defined in the Master Agreement) and sanofi-aventis U.S. LLC
shall be responsible for all decisions relating to distribution and commercialization of the Products in Territory B1 as of the Effective Date; and 
 WHEREAS, the Restructuring is not intended to change the overall governance, operating, and financial principles of the alliance with respect to Clopidogrel or Clopidogrel Products in the United States of
America other than as set forth herein. 
 NOW THEREFORE, the Parties, in consideration of the foregoing and other good and
valuable consideration (the receipt and sufficiency of which are hereby acknowledged by each of the Parties) hereby agree by mutual consent: 
  

	 	1.	Amendments. The Parties hereby agree that the Partnership Agreement shall be amended as of the Effective Date to provide the following: 

*CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

	 	a.	All countries other than the United States of America shall no longer be included within the definition of “Territory B” in the Partnership Agreement and, as
such, Section 1.01 of the Partnership Agreement shall be amended to remove Territory B1 (as defined in the Master Agreement) and all references to “Territory B” throughout the Partnership Agreement shall mean solely the United States
of America (which, in any event, shall not include Irbesartan in the United States of America). 

  

	 	b.	The definition of “Product” or “Products” in Section 1.01 of the Partnership Agreement, and all references to “Product” throughout
the Partnership Agreement, shall mean Clopidogrel and the Clopidogrel Products only. All references to “Irbesartan” or “Irbesartan Products” or “Irbesartan Products in the United States of America” throughout the
Partnership Agreement shall be deleted in their entirety, as the purpose of JVB shall be the development, manufacturing, commercialization and sale of the Clopidogrel Product in the United States of America (which includes Puerto Rico).

  

	 	c.	Section 2.03 of the Partnership Agreement shall be amended and restated in its entirety as follows: 

“Section 2.03. Purpose. The businesses and purposes of the Partnership shall be (a) to carry on all activities related
to the development, manufacturing, commercialization and sale of the Clopidogrel Products in Territory B (which, for the avoidance of doubt, means the United States of America (which includes Puerto Rico), and (b) to enter into, make and
perform all such contracts and other undertakings, and to engage in all such activities and transactions, as may be necessary or desirable to conduct such businesses and activities.” 

 

	 	d.	A new Section 6.09 shall be added to the Partnership Agreement to provide the following: 

“Section 6.09. Tax Matters Following Termination. Following the termination of the Partnership Agreement, the [*] shall
retain the responsibilities of Tax Matters partner with respect to all tax periods ending on or prior to the date of such termination. In connection therewith, the [*] shall: (i) promptly provide the [*] with copies of notices or other
materials from, and inform the [*] of discussions with, U.S. federal and state tax authorities; (ii) provide the [*] with notice of all scheduled administrative proceedings, including, without limitation, meetings with agents of such tax
authorities, technical advice, conferences and appellate hearings, in each case promptly after receiving notice of the scheduling of such proceedings and (ii) not agree to any settlement agreement with such tax authority with respect to
JVB-related items of income, gain, loss or deduction without the [*] prior written consent; provided, that the [*] may request extensions to file all tax returns or statements without the [*] prior written consent (and the [*] shall provide
the [*] with notice of any such requests). 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

2 

	 	e.	The first sentence of Section 10.2(b) of the Partnership Agreement shall be deleted in its entirety. 

 

	 	f.	Section 12.01 of the Partnership Agreement shall be amended and restated in its entirety as follows: 

“Section 12.01. Notices. All notices, requests, claims, demands and other communications hereunder (collectively,
“Notices”) shall be in writing, shall be in the English language, and shall be given or made by delivery in person, by courier services, by facsimile (with receipt confirmed) or by registered or certified mail (return receipt
requested, with postage prepaid), to the respective Persons at the following addresses: 
 If to the Partnership
or the BMS Partner, to: 
 Bristol-Myers Squibb Investco, L.L.C. 

c/o Bristol-Myers Squibb Company 

Route 206 & Province Line Road 

Princeton, NJ 08543-4000 USA 
 Attention: Sanofi Alliance Manager 
 with a copy (which shall not
constitute notice), to: 
 Wilmer Cutler Pickering Hale and Dorr LLP 

7 World Trade Center 
 250 Greenwich Street 
 New York, NY 10007 USA 

Attn: [omitted] 
 Email: [omitted] 
 and 

If to the Sanofi Partner, to: 
 sanofi-aventis U.S. LLC 
 55 Corporate Drive 

Bridgewater, NJ 08807 USA 
 Attn: [omitted] 
 Facsimile: (908) 981-5705 

with a copy (which shall not constitute notice), to: 

sanofi-aventis U.S. LLC 
 55 Corporate Drive 
 Bridgewater, NJ 08807 USA 

Attn: [omitted] 
 Facsimile: (908) 981-7833 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

3 

 and 

Weil, Gotshal & Manges LLP 

767 Fifth Avenue 
 New York, NY 10153 USA 
 Attn: [omitted] 

Facsimile: (212) 310-8007 
 Email: [omitted] 
  

	 	2.	Remainder of the Agreement. Except as explicitly amended hereby, other provisions of the Partnership Agreement (as otherwise amended, modified, supplemented or
restated prior to the Effective Date) shall remain unchanged. 

  

	 	3.	Representations and Warranties. Each of the Parties hereto represents and warrants to each other as of the date hereof that (a) it has the requisite
authority and power to enter into this Amendment and (b) the execution and delivery of this Amendment has been duly authorized and constitutes its legal, valid and binding obligation, enforceable against it in accordance with its terms.

  

	 	4.	Counterparts. This Amendment may be executed in any number of counterparts (and by different parties hereto on different counterparts), each of which shall
constitute an original, but all of which when taken together shall constitute a single contract. 

  

	 	5.	Successors and Assigns. The terms of this Agreement and the respective rights and obligations of the Parties hereunder shall be binding upon, and inure to the
benefit of, their respective successors and assigns. 

 [Remainder of Page Intentionally Left Blank]

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

4 

 IN WITNESS WHEREOF, this Agreement has been duly executed as of the date first written
above. 
  

			
	SANOFI-AVENTIS U.S. LLC
		
	By:	 	 /s/ T. Saugier

		 	 Name: T. Saugier
 Title:
Authorized representative

	
	BRISTOL-MYERS SQUIBB INVESTCO, L.L.C.
		
	By:	 	 /s/ Katherine Kelly

		 	 Name: Katherine Kelly
 Title:
Secretary

 [Signature Page to Territory B Partnership Agreement Amendment] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]